Knockdown of HOXA10 reverses the multidrug resistance of human chronic mylogenous leukemia K562/ADM cells by downregulating P-gp and MRP-1

Corrigendum in: /10.3892/ijmm.2023.5315

  • Authors:
    • Ying-Jie Yi
    • Xiu-Hong Jia
    • Jian-Yong Wang
    • You-Jie Li
    • Hong Wang
    • Shu-Yang Xie
  • View Affiliations

  • Published online on: March 24, 2016     https://doi.org/10.3892/ijmm.2016.2539
  • Pages: 1405-1411
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Multidrug resistance (MDR) of leukemia cells is a major obstacle in chemotherapeutic treatment. The high expression and constitutive activation of P-glycoprotein (P-gp) and multidrug resistance protein-1 (MRP-1) have been reported to play a vital role in enhancing cell resistance to anticancer drugs in many tumors. The present study aimed to investigate the reversal of MDR by silencing homeobox A10 (HOXA10) in adriamycin (ADR)-resistant human chronic myelogenous leukemia (CML) K562/ADM cells by modulating the expression of P-gp and MRP-1. K562/ADM cells were stably transfected with HOXA10-targeted short hairpin RNA (shRNA). The results of reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis showed that the mRNA and protein expression of HOXA10 was markedly suppressed following transfection with a shRNA-containing vector. The sensitivity of the K562/ADM cells to ADR was enhanced by the silencing of HOXA10, due to the increased intracellular accumulation of ADR. The accumulation of ADR induced by the silencing of HOXA10 may be due to the downregulation of P-gp and MRP-1. Western blot analysis revealed that downregulating HOXA10 inhibited the protein expression of P-gp and MRP-1. Taken together, these results suggest that knockdown of HOXA10 combats resistance and that HOXA10 is a potential target for resistant human CML.
View Figures
View References

Related Articles

Journal Cover

May-2016
Volume 37 Issue 5

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yi Y, Jia X, Wang J, Li Y, Wang H and Xie S: Knockdown of HOXA10 reverses the multidrug resistance of human chronic mylogenous leukemia K562/ADM cells by downregulating P-gp and MRP-1 Corrigendum in /10.3892/ijmm.2023.5315. Int J Mol Med 37: 1405-1411, 2016.
APA
Yi, Y., Jia, X., Wang, J., Li, Y., Wang, H., & Xie, S. (2016). Knockdown of HOXA10 reverses the multidrug resistance of human chronic mylogenous leukemia K562/ADM cells by downregulating P-gp and MRP-1 Corrigendum in /10.3892/ijmm.2023.5315. International Journal of Molecular Medicine, 37, 1405-1411. https://doi.org/10.3892/ijmm.2016.2539
MLA
Yi, Y., Jia, X., Wang, J., Li, Y., Wang, H., Xie, S."Knockdown of HOXA10 reverses the multidrug resistance of human chronic mylogenous leukemia K562/ADM cells by downregulating P-gp and MRP-1 Corrigendum in /10.3892/ijmm.2023.5315". International Journal of Molecular Medicine 37.5 (2016): 1405-1411.
Chicago
Yi, Y., Jia, X., Wang, J., Li, Y., Wang, H., Xie, S."Knockdown of HOXA10 reverses the multidrug resistance of human chronic mylogenous leukemia K562/ADM cells by downregulating P-gp and MRP-1 Corrigendum in /10.3892/ijmm.2023.5315". International Journal of Molecular Medicine 37, no. 5 (2016): 1405-1411. https://doi.org/10.3892/ijmm.2016.2539